Michael D. Green, M.D., M.P.H.

  • Professor of Pediatrics and Surgery
  • Director, Pediatric Human Immunodeficiency Virus (HIV) Center
  • Codirector, Transplant Infectious Diseases

Major Lectureships and Seminars

  • EBV and PTLD: Prevention, Diagnosis and Management. Transplant Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh, Pa., October 14, 2016
  • EBV and PTLD: Essential Concepts and Breaking News. Pediatric Grand Rounds. Cleveland Clinic. Cleveland, Oh., November 1, 2016
  • Infectious Complications of Organ Transplantation in Children. Cleveland Clinic. Cleveland, Oh., November 1, 2016
  • EBV and PTLD: Essential Concepts and Breaking News: Infectious Diseases Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh, Pa., February 9, 2017
  • Infections in Children on Extrinsic Immune Suppression: Advice to the Primary Care Physician
    & Non-Transplant Subspecialist. Amos Christie Annual Lectureship. Vanderbilt Pediatric Grand Rounds. Nashville, Tn., May 23, 2017

Professional Affiliations/Society Memberships

  • American Pediatric Society
  • American Society for Microbiology
  • International Pediatric Transplantation Association
  • Fellow, Infectious Diseases Society of America
  • Fellow, American Society of Transplantation
  • Society for Pediatric Research
  • Pediatric Infectious Diseases Society

Education & Training

  • Medical School: University of Illinois College of Medicine
  • Residency: University of Pittsburgh School of Medicine
  • Fellowship: University of Pittsburgh School of Medicine

Representative Publications

Research Interests

The major focus of Michael Green’s laboratory has been on the epidemiology of antimicrobial resistance in children the in hospital and community settings. His laboratory is currently funded through multiple NIH grants and contracts to carry out this work. Green’s interest in antibiotic resistance is further reflected in the efforts of the Children’s Hospital of Pittsburgh of UPMC Antimicrobial Stewardship Program (ASP), which he directs. More recently, he has expanded his efforts on his longstanding interest in infections in immunocompromised hosts, including transplant patients and children receiving immune suppression for autoimmune disease. The following summary of his major research projects provides an update on his current activities.

Short-course Therapy for Urinary Tract Infection (UTI) in Children (SCOUT). This NIH-funded study is a multicenter, randomized, controlled trial to determine whether short-course antimicrobial therapy (5 days) is non-inferior to standard-course antimicrobial therapy (10 days) in children with UTI. Green’s role in the study is to evaluate serial surveillance cultures from participants to track potential differences in the development of antibiotic resistance in isolates of Escherichia coli and Klebsiella pneumoniae. Resistant isolates will undergo evaluation for mechanism of resistance. Green is also performing surveillance screening for colonization with carbapenem-resistant Enterobacteriaceae to provide a sense of the prevalence of colonization in children with these increasingly important gram-negative bacteria.

Difference in Infecting and Colonizing Enterobacteriaceae from Short-course Versus Standard Therapy. This R21 study (principal investigator [PI]: Scott Weissman, University of Washington) is an NIH-funded ancillary study whose goal is to carry out a detailed molecular analysis of bacterial isolates recovered as part of the SCOUT study to evaluate the impact of antibiotic drug and length of therapy on the indigenous flora and the likelihood of antimicrobial resistance and to assess the presence of virulence factors associated with UTI. Although accrual of specimens and funding for this study were completed in spring 2015, analysis of results from this ancillary study cannot begin until accrual for the primary study is completed.

Type 1 Diabetes TrialNet/University of South Florida (Data Coordinating Center). Green continues to serve as one of two infectious disease consultants for the NIH Type I Diabetes TrialNet. This clinical trial network evaluates potential interventions aimed at modifying the natural history of insulin-dependent diabetes mellitus in children. Many of these interventions include immunosuppressive regimens and are therefore potentially associated with the development of opportunistic infections. Green’s role as infectious disease consultant remains formally integrated into the protocol-development and approval process for TrialNet. Additionally, the work has resulted in several infectious diseases related publications and the infectious diseases group within TrialNet continues to develop ancillary studies to evaluate the impact of immunosuppression in subsequent TrialNet protocols.

Improving Diagnosis and Treatment of Pediatric Candidiasis. The goal of this NIH-funded, multicenter study is to develop new evidence-based treatment guidelines for invasive candidiasis in children. It retrospectively collects data to compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis, as well as to characterize the incidence of all invasive candidiasis infections in pediatric patients. Green has served as the site PI since CHP’s involvement in this study began in 2015.

Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia. The goals of this NIH-funded, prospective, multicenter study include defining the operating characteristics of fungal biomarker assays in pediatric patients at high risk for developing invasive candidiasis, determining how fungal biomarkers change in response to antifungal treatment, and creating a biobank of blood samples from pediatric patients who are at high risk for or have invasive candidiasis for future testing of fungal biomarker assays and development of new fungal biomarker assays. Green has served as the site PI since CHP’s participation in this study began in 2015.

A Multi-Center Prospective Study of Human Adenovirus Infection and Disease in Pediatric Human Stem Cell Transplant Recipients. The goal of this NIH-funded multicenter BAA is to prospectively study the epidemiology of adenovirus after pediatric HSCT during their first six months after HSCT for development of adenovirus infection and disease. Green is the site Co-PI for this study

A Phase II, Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients > 6 Years of Age. The purpose of this NIH-funded phase II multicenter, prospective, randomized, double-blind study is to assess the clinical and antiviral efficacy and safety of nitazoxanide for the treatment of acute and chronic norovirus in hematopoietic stem cell and solid organ transplant recipients. Green is site Co-PI for this study

NIH/University of Pittsburgh Clinical and Translational Science Institute. The goal of the Clinical and Translational Science Institute is to provide the clinical research infrastructure for medical scientists who conduct patient-oriented, research-related care for disorders of infancy, childhood, and adolescence. Green’s current role continues to be to provide individual support and workshops on informed consent to new clinical investigators and their research staff.

CV

Division